Wells Fargo analyst Brandon Couillard lowered the firm’s price target on Bio-Techne (TECH) to $62 from $76 and keeps an Overweight rating on the shares. The firm notes the shares fell sharply on the disappointing Q3 miss and lower FY26 organic guide down, driven by softer biotech demand that is lagging the biotech funding recovery that started in the second half of 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH: